Bladder Cancer Case Control Study of Arsenic in Water
NCT00011518 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600
Last updated 2006-03-23
Summary
This study is examining the relationship between ingested arsenic and bladder cancer in two areas of California where a large percentage of the population was exposed to drinking water containing arsenic at low to moderate levels.
Conditions
Sponsors & Collaborators
-
National Institute of Environmental Health Sciences (NIEHS)
lead NIH
Eligibility
- Min Age
- 20 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 1997-10-31
- Completion
- 2001-07-31
Countries
- United States
Study Locations
More Related Trials
-
Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer
NCT00425386 ·Status: COMPLETED ·Phase: PHASE2
-
Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer
NCT00354250 ·Status: COMPLETED ·Phase: PHASE2
-
Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer
NCT00492258 ·Status: COMPLETED ·Phase: PHASE3
-
Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
NCT00717587 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719 ·Status: RECRUITING ·Phase: PHASE3
-
Study of CP-461 in Patients With Advanced Renal Cell Cancer
NCT00036036 ·Status: COMPLETED ·Phase: PHASE2
-
S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer
NCT00058318 ·Status: COMPLETED ·Phase: PHASE2
-
Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging
NCT04021238 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer
NCT01255137 ·Status: COMPLETED ·Phase: PHASE2
-
Carboxyamidotriazole in Treating Patients With Advanced Kidney Cancer
NCT00005045 ·Status: COMPLETED ·Phase: PHASE2
-
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
NCT00121251 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Activity Study of Sunitinib In Metastatic Pretreated Urothelial Cancer
NCT00818350 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT05119335 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma
NCT00423332 ·Status: COMPLETED ·Phase: PHASE2
-
UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer
NCT00570232 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
NCT05048212 ·Status: RECRUITING ·Phase: PHASE2
-
Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer
NCT00005027 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
NCT02386111 ·Status: TERMINATED ·Phase: PHASE1
-
Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
NCT00514228 ·Status: COMPLETED ·Phase: PHASE2
-
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
NCT02903914 ·Status: COMPLETED ·Phase: PHASE1
-
An Exploratory Correlative Study of Biomarkers in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed After Sunitinib Therapy
NCT00538772 ·Status: WITHDRAWN
-
Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma
NCT00389285 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
NCT01100242 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase II Study of AS1411 in Renal Cell Carcinoma
NCT00740441 ·Status: UNKNOWN ·Phase: PHASE2
-
Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer
NCT01158222 ·Status: COMPLETED ·Phase: PHASE2